• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Global Blood Ther (NQ: GBT )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Global Blood Ther

    < Previous 1 2 3 4 Next >
    50 Biggest Movers From Yesterday
    Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 143.8% to settle at $12.19 on Tuesday after the company priced its IPO at $5 per share, MIND Technology, Inc. (NASDAQ: MIND... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
    Via Benzinga
    Global Blood Therapeutics Earnings Perspective: Return On Capital Employed
    Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q3 sales of $52.05 million. Earnings fell to a loss of $70.99 million, resulting in a 2.01% decrease from last... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
    Via Benzinga
    Exposures COVID-19
    Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
    Upgrades For CarMax Inc (NYSE: 
    Via Benzinga
    Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
    A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
    Via Benzinga
    Exposures Product Safety
    The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
    The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
    Via Benzinga
    Exposures Product Safety
    Global Blood Therapeutics (GBT) Q3 2021 Earnings Call Transcript
    GBT earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
    Via Benzinga
    Exposures COVID-19
    See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
    Jefferies initiated coverage of Global Blood Therapeutics Inc (NASDAQ: GBT) with a Buy rating and $68 price target. The analyst sees an upside of almost 145... 
    Via Benzinga
    The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
    Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
    Upgrades For State Street Corporation (NYSE: 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Gainers TransCode Therapeutics (NASDAQ:RNAZ 
    Via Benzinga
    The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
    Via Benzinga
    Exposures Product Safety
    Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use
    The FDA has accepted Global Blood Therapeutics Inc's (GBT) (NASDAQ: GBT) supplemental application seeking accelerated approval for Oxbryta (voxelotor) for... 
    Via Benzinga
    Exposures Product Safety
    The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
    Via Benzinga
    Why Shares of Global Blood Therapeutics Are Soaring Today
    The biotech company has only one drug, Oxbryta, on the market, to treat sickle cell disease. Its shares were up Monday after falling on Friday. 
    Via The Motley Fool
    The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
    Via Benzinga
    Exposures COVID-19
    88 Biggest Movers From Yesterday
    Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
    Via Benzinga
    Why Global Blood Therapeutics Is Rallying Today
    This heavily shorted biotech finally had some good news. 
    Via The Motley Fool
    Global Blood Shoots 17% Higher As Q2 Earnings Beat Estimates; Analyst Upgrades Stock
    Global Blood Therapeutics Inc (NASDAQ: GBT) reported Q2 Oxbryta (voxelotor) sales of $47.55 million, +51% Y/Y, beating the consensus of $43.84 million. On a sequential... 
    Via Benzinga
    Topics Earnings
    Exposures Financial
    Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021
    Upgrades For Meritage Homes Corp (NYSE: 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6... 
    Via Benzinga
    30 Stocks Moving in Wednesday's Pre-Market Session
    Gainers Alterity Therapeutics Limited (NASDAQ: ATHE) shares rose 34.8% to $1.84 in pre-market trading after gaining around 3% on Tuesday. Wheeler Real Estate Investment Trust,... 
    Via Benzinga
    Global Blood Therapeutics (GBT) Q2 2021 Earnings Call Transcript
    GBT earnings call for the period ending June 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years
    Global Blood Therapeutics Inc (NASDAQ: GBT) has submitted a supplemental marketing application to the FDA seeking accelerated approval for Oxbryta (voxelotor) for... 
    Via Benzinga
    Exposures Product Safety
    The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands (NYSE:LVS) was the largest firm by market cap to set a new 52-... 
    Via Benzinga
    The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
    Via Benzinga
    The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.